In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Tango Therapeutics Inc (NASDAQ: TNGX) closed the day trading at $7.01 up 3.85% from the previous closing price of $6.75. In other words, the price has increased by $3.85 from its previous closing price. On the day, 0.73 million shares were traded. TNGX stock price reached its highest trading level at $7.04 during the session, while it also had its lowest trading level at $6.6.
Ratios:
For a better understanding of TNGX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.75 and its Current Ratio is at 4.75. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $11.
On July 17, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $19.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 19 ’25 when Third Rock Ventures IV, L.P. sold 1,100,000 shares for $7.01 per share. The transaction valued at 7,712,760 led to the insider holds 15,759,075 shares of the business.
Third Rock Ventures IV, L.P. bought 1,100,000 shares of TNGX for $7,656,000 on Aug 19 ’25. On Feb 04 ’25, another insider, Barry Douglas, who serves as the General Counsel of the company, sold 2,774 shares for $2.99 each. As a result, the insider received 8,289 and left with 68,570 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNGX now has a Market Capitalization of 779932608 and an Enterprise Value of 634157312. For the stock, the TTM Price-to-Sale (P/S) ratio is 32.10 while its Price-to-Book (P/B) ratio in mrq is 5.76. Its current Enterprise Value per Revenue stands at 26.101 whereas that against EBITDA is -4.097.
Stock Price History:
The Beta on a monthly basis for TNGX is 1.64, which has changed by -0.39412272 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, TNGX has reached a high of $12.02, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 15.48%, while the 200-Day Moving Average is calculated to be 105.10%.
Shares Statistics:
Over the past 3-months, TNGX traded about 2.70M shares per day on average, while over the past 10 days, TNGX traded about 1327060 shares per day. A total of 110.87M shares are outstanding, with a floating share count of 61.39M. Insiders hold about 44.82% of the company’s shares, while institutions hold 73.25% stake in the company. Shares short for TNGX as of 1753920000 were 22475890 with a Short Ratio of 8.33, compared to 1751241600 on 21193333. Therefore, it implies a Short% of Shares Outstanding of 22475890 and a Short% of Float of 24.239999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Its stock is currently analyzed by 8.0 different market analysts. The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.25 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$0.95 and -$1.49 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is -$1.42, with 7.0 analysts recommending between -$1.1 and -$1.83.
Revenue Estimates
8 analysts predict $41.34M in revenue for the current quarter. It ranges from a high estimate of $53.81M to a low estimate of $3.18M. As of the current estimate, Tango Therapeutics Inc’s year-ago sales were $11.61M
A total of 8 analysts have provided revenue estimates for TNGX’s current fiscal year. The highest revenue estimate was $62.4M, while the lowest revenue estimate was $14.94M, resulting in an average revenue estimate of $53.92M. In the same quarter a year ago, actual revenue was $42.07M
